We describe a case of symptomatic primary Cytomegalovirus infection in a HIV-positive pregnant woman on antiretroviral treatment with a CD4 count >200 Â 10 6 /l requiring intravenous ganciclovir. No adverse consequences from ganciclovir or evidence of congenital Cytomegalovirus infection were found.
Introduction
Pregnancy-related immunosuppression predisposes women to infection. Symptomatic primary Cytomegalovirus (CMV) infection is rare in pregnancy but should be considered in pregnant women presenting with 'viral' symptoms, particularly those immunocompromised.
Case report
A 21-year-old pregnant woman with a three-year history of HIV-1 developed pyrexia, cough, chest pain and epigastric pain at 30 weeks gestation.
She was treatment naı¨ve without evidence of HIV resistance. At first antenatal visit (13 weeks gestation), CD4 count was 862 Â 10 6 /l (53%). HIV viral load (VL) was 4645 copies/ml. Atazanavir, ritonavir and zidovudine/lamivudine were commenced at 17 weeks gestation.
On examination, the patient was pyrexial (38.7 C), tachypnoeic (respiratory rate 20/min) with bilateral crepitations and tachycardic (pulse 123 beats/min). Oxygen saturations were 98% in room air. Investigations revealed a leukocytosis of 15.2 Â 10 9 /l, neutrophils 13.9 Â 10 9 /l, C-reactive protein (CRP) 29 mg/l and elevated liver enzymes. Chest x-ray showed minor linear shadowing at the right lung base. She was diagnosed with a respiratory tract infection and commenced on broad-spectrum antimicrobial therapy, but remained febrile.
Serology revealed CMV IgM and CMV IgG positivity with an IgG avidity index of 0.174, indicating recent infection. CMV DNA VL was 97,129 copies/ml (cpm). Retrospectively-tested booking antenatal serology was CMV-negative. Other viral studies were negative, confirming symptomatic primary CMV infection. Of note, at 18 weeks gestation, the patient was admitted with a diffuse, maculo-papular, erythematous rash with lowgrade pyrexia attributed to recent initiation of antiretroviral therapy. However, this likely represented CMV seroconversion illness.
Following careful consideration, 300 mg ganciclovir (5 mg/kg) intravenous (IV) 12-hourly was commenced. The patient became afebrile, and liver enzymes, white cell count and CRP normalised. IV treatment continued for seven days, followed by oral valgancyclovir 900 mg twice daily until delivery. Zidovudine/lamivudine was changed to tenofivir/emtricitabine to avoid interaction with valgancyclovir. CMV DNA was undetectable four weeks after ganciclovir initiation.
Serial foetal ultrasounds showed reduced foetal growth. Pericardial effusion and right ventricular hypertrophy were initially noted but spontaneously resolved prior to delivery. Labour was induced at 37 weeks gestation. The female infant was small for gestational age (2.07 kg) but otherwise clinically unremarkable. Neonatal full blood count and liver enzymes were normal. Congenital CMV infection was out-ruled with infant urine and plasma CMV DNA undetectable at 3, 14 and 42 days of life. Infant HIV status was negative.
Discussion
Congenital CMV affects 0.3-2.4% of all live births in developed countries. 1 Seroconversion occurs in 1-4% of all pregnancies and is higher in women who are of low-socioeconomic status. 2 Primary CMV infection during pregnancy carries a high risk (30-40%) of congenital infection; the risk of congenital infection associated with CMV reactivation is much lower (0.5-1.4%), 3 but the consequences to the infant are equally severe. 4 Infection in early pregnancy carries a higher risk of an affected foetus than later infection. 5 Complications include intrauterine death, sensorineural hearing loss (SNHL) and neurodevelopmental delay. 5 While only 10-20% of affected newborns have symptomatic infection, 5-15% develop late sequelae during the first years of life, namely SNHL. 3, 5 CMV seroprevalence among women of childbearing age varies from 35% to 95% depending on country of origin, socioeconomic status, age, race, breastfeeding practices, sexual activity and use of group childcare facilities. 4, 6 CMV transmission occurs via close, nonsexual contact, sexual activity, breast-feeding, blood transfusions, organ transplantation and contact with the urine and saliva of young children. 7 CMV seroprevalence among Irish pregnant women is 30.4%, leaving most at risk of primary infection. 4 The patient's CD4 count was 700 Â 10 6 /l, and HIV VL <40 at the estimated time of CMV seroconversion. Pregnancy-associated depression of cell-mediated immunity (CMI) may interfere with the response to specific infectious agents. 8 One study showed specific impairment in CMI to CMV in mothers of infants with congenital CMV infection. 9 In another, CMV seropositive parturients had markedly depressed lymphocyte proliferative responses, suggesting reactivation of latent CMV related to transient depression of CMV-specific cellular immunity. 10 We postulate that pregnancy-related CMI suppression contributed to symptomatic CMV infection in a patient with existing immune dysfunction.
Ganciclovir is not licensed in pregnancy, as animal studies have demonstrated teratogenicity; however, a number of published case reports describe the safe use of ganciclovir during pregnancy without adverse foetal outcome. 11, 12 Our HIV-infected patient had a high CMV VL (97,129 cpm) and was clinically symptomatic, hence the decision to treat for both maternal and foetal benefit. The patient was beyond trimester one when drug toxicity to the foetus is greatest. Both IV and oral anti-CMV antivirals were administered until delivery without adverse foetal outcome.
This report describes a rare case of primary CMV infection in a HIV-infected woman on antiretrovirals in pregnancy. CMV-specific antiviral therapy was safely administered with a good outcome for both mother and child.
